FY2025 · ended Dec 31, 2025 · Revenue $20.96M, -5.7% YoY · Filed Mar 25, 2026
MaxCyte, Inc. (MXCT) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $21.0 million and a net loss of $44.6 million. Free cash flow was -$36.2 million. As of Jun 30, 2026 it held $141.9 million in cash and investments and $17.3 million in total debt.
Revenue (TTM)
$18.83M
-19.0% vs year-ago TTM
Net income (TTM)
$-35.64M
+20.4% vs year-ago TTM
Operating cash flow (TTM)
$-22.98M
+37.0% vs year-ago TTM
Free cash flow (TTM)
$-23.64M
+38.2% vs year-ago TTM
EPS (TTM)
$-0.33
+21.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
106.86M
+0.8% vs prior year
Net cash
$124.67M
as of Jun 30, 2026
Operating margin
-222.0%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MXCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1287098
- Former names
- MAXCYTE INC (until Sep 18, 2008)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $21.0M | $22.2M | $19.5M | $28.7M | $21.6M |
| Operating income | -$51.9M | -$51.2M | -$48.3M | -$27.4M | -$18.2M |
| Net income | -$44.6M | -$41.1M | -$37.9M | -$23.6M | -$19.1M |
| Diluted EPS | -$0.42 | -$0.39 | -$0.37 | -$0.23 | -$0.21 |
| Operating cash flow | -$34.4M | -$27.6M | -$21.7M | -$14.8M | -$10.7M |
| Free cash flow | -$36.2M | -$29.3M | -$25.4M | -$33.3M | -$14.5M |
| Total assets | $202.5M | $239.5M | $268.3M | $286.7M | $284.1M |
| Total liabilities | $31.0M | $33.2M | $36.1M | $32.7M | $21.2M |
| Stockholders' equity | $171.5M | $206.3M | $232.2M | $254.0M | $262.9M |
| Cash and investments | $155.6M | $190.3M | $211.2M | $227.3M | $255.0M |
| Total debt | $17.9M | $18.0M | $18.7M | $16.1M | $5.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 14, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Listing notice
|
Jun 16, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 336 MaxCyte, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.